13F Pro13F Pro

Rosalind Advisors, Inc.

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1622627
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare100.0%$266.2M

AUM History

13fpro.ai/research/fund/rosalind-advisors-inc-1622627

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/rosalind-advisors-inc-1622627

Rosalind Advisors, Inc. 13F holdings — Q2 2026

$379.1M portfolio (+52.3% QoQ) · 35 holdings · Q2 2026 13F · top 10 are 75% of the stock portfolio

Includes $112.9M of put/call options ($112.4M puts, $506K calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $266.2M. Weights use the stock portfolio.

All holdings — Rosalind Advisors, Inc. (Q2 2026)

35 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
— PUTISHARES TR - PUT$110.0MNew
MDWD$MDWDMediWound Ltd.$11.0M—
CLDX$CLDXCelldex Therapeutics, Inc.$7.4M-39%
BCRX$BCRXBIOCRYST PHARMACEUTICALS INC$7.2M-22%
PROF$PROFProfound Medical Corp.$5.5M—
TLPH$TLPHTALPHERA, INC.$5.3M+54%
AVIR$AVIRAtea Pharmaceuticals, Inc.$5.0M-9%
MYO$MYOMYOMO, INC.$3.8M-5%
OVID$OVIDOvid Therapeutics Inc.$3.0M—
NRXS$NRXSNeuraxis, INC$3.0M+78%
ABVX$ABVXAbivax S.A.adr$2.8MNew
NSPR$NSPRInspireMD, Inc.$2.7M—
RGNT$RGNTREGENTIS BIOMATERIALS LTD.$2.5M+179%
— PUTSELLAS LIFE SCIENCES GROUP INC - PUT$2.3MNew
PYPD$PYPDPolyPid Ltd.$2.0M-35%

What changed in Q2 2026

Against the previous quarter's 13F: 9 new, 7 added to, 11 trimmed, 12 sold out. Share-count changes; largest moves by dollar size first.

New positions (9)

  • PUTISHARES TR - PUT$110.0M

    first bought this quarter

  • ABVX$ABVXAbivax S.A.$2.8M

    first bought this quarter

  • PUTSELLAS LIFE SCIENCES GROUP INC - PUT$2.3M

    first bought this quarter

  • SPRB$SPRBSPRUCE BIOSCIENCES, INC.$1.1M

    first bought this quarter

  • PEPG$PEPGPepGen Inc.$630K

    first bought this quarter

  • CGON$CGONCALLCG Oncology, Inc.$375K

    first bought this quarter

+3 more in the Excel export

Added to (7)

  • VSTM$VSTMVerastem, Inc.+86%

    now $15.2M · held 6+ qtrs, 2 adds in a row

  • FENC$FENCFENNEC PHARMACEUTICALS INC.+10%

    now $34.3M · held 6+ qtrs, 5 adds in a row

  • HELP$HELPHelus Pharma Inc.+28%

    now $12.9M · held 6+ qtrs

  • TLPH$TLPHTALPHERA, INC.+54%

    now $5.3M · held 6+ qtrs

  • RGNT$RGNTREGENTIS BIOMATERIALS LTD.+179%

    now $2.5M · held 3 qtrs

  • NRXS$NRXSNeuraxis, INC+78%

    now $3.0M · held 3 qtrs

+1 more in the Excel export

Trimmed (11)

  • PCVX$PCVXVaxcyte, Inc.-31%

    now $11.6M · held 2 qtrs

  • CLDX$CLDXCelldex Therapeutics, Inc.-39%

    now $7.4M · held 2 qtrs

  • XERS$XERSXeris Biopharma Holdings, Inc.-10%

    now $23.0M · held 6+ qtrs

  • BCRX$BCRXBIOCRYST PHARMACEUTICALS INC-22%

    now $7.2M · held 2 qtrs

  • OKUR$OKUROnKure Therapeutics, Inc.-66%

    now $684K · held 3 qtrs, 2 trims in a row

  • PYPD$PYPDPolyPid Ltd.-35%

    now $2.0M · held 6+ qtrs, 5 trims in a row

+5 more in the Excel export

Sold out (12)

  • CGON$CGONCG Oncology, Inc.was $6.8M

    held 4 qtrs

  • VRDN$VRDNViridian Therapeutics, Inc.\DEwas $4.9M

    held 5+ qtrs

  • REPL$REPLCALLReplimune Group, Inc.was $2.7M
  • DFTX$DFTXDefinium Therapeutics, Inc.was $2.4M

    held 1 qtr

  • LPCN$LPCNLipocine Inc.was $1.8M

    held 1 qtr

  • AVTX$AVTXAvalo Therapeutics, Inc.was $1.1M

    held 1 qtr

+6 more in the Excel export

Share

Holdings by quarter

Every 13F Rosalind Advisors, Inc. has filed, 10 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Rosalind Advisors?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Rosalind Advisors's top 20 holdings: 40/100 (our AI quality score, weighted by position size; 10 of the 20 are scored)

Top 10 since filing

-4.5%

Value-weighted move of the 10 largest stock positions

Turnover

9%

Last quarter; 73% over the last 4

Top 10 weight

75%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

78%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Rosalind Advisors, Inc. disclosed 35 positions worth $379.1M in its Form 13F-HR for Q2 2026 — $266.2M in common stock plus $112.9M of put/call option positions (reported at underlying notional value, not premium at risk), led by $DCTH (DELCATH SYSTEMS, INC.) at 15.6% of the equity portfolio, followed by $FENC and $XERS. During the quarter the fund opened 9 new positions and exited 12 and a full exit from $CGON. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Rosalind Advisors, Inc.’s Form 13F-HR filing with the SEC under CIK 1622627.

Funds like this

managers whose biggest positions overlap Rosalind Advisors's
RA CAPITAL MANAGEMENT, L.P.$11.51B 13F book · 3 shared top holdingsPCVXBCRXABVXTCG Crossover Management, LLC$4.16B 13F book · 5 shared top holdingsBCRXVORSVRAABVXBain Capital Life Sciences Investors, LLC$1.68B 13F book · 3 shared top holdingsSVRAXFORAVIRKynam Capital Management, LP$1.81B 13F book · 3 shared top holdingsPCVXCLDXBCRXNEA Management Company, LLC$1.59B 13F book · 3 shared top holdingsSVRAXFOROKURSaturn V Capital Management LP$697.47M 13F book · 4 shared top holdingsXFORPCVXABVXOVID

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Rosalind Advisors, Inc.

13F Pro is an AI hedge fund tracker and stock research platform. For Rosalind Advisors, Inc. (SEC CIK: 1622627), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Rosalind Advisors, Inc.'s portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.